Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAT1 | P18440 | 8/20 | 0.56 |
| ▸ | MYC | P01106 | 2/20 | 0.56 |
| ▸ | MAX | P61244 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339497 | 1.00 | NAT1 (0.56) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL622422 | 0.76 | HTT (0.56) | PDE3ARAB9AKMT2A | |
| SCHEMBL5342147 | 0.76 | CSNK2A2 (0.61) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL5342146 | 0.76 | CSNK2A2 (0.61) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL2917661 | 0.75 | HTT (0.55) | RAB9A | |
| SCHEMBL5339919 | 0.74 | NAT1 (0.53) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL5339921 | 0.74 | NAT1 (0.53) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL6781138 | 0.72 | NAT1 (1.00) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL13499575 | 0.72 | PTP4A3 (0.71) | NAT1MYCMAXPDE4BPDE3A | |
| SCHEMBL5981766 | 0.72 | NAT1 (0.65) | NAT1MYCMAXPDE4BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | NAT1 2652/4885MYC 4004/4885MAX 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.